Literature DB >> 25399714

Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues.

N K Gillis1, F Innocenti2.   

Abstract

Pharmacogenetics is an area of research that has potential to greatly benefit patients. However, the routine use of diagnostic pharmacogenetic testing to inform treatment decisions is limited. Here we discuss the determination of clinical utility of pharmacogenetic testing and the level of evidence required to support translation into clinical practice.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25399714     DOI： 10.1038/clpt.2014.185

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors:  Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal:  Pharm Res       Date:  2017-02-24       Impact factor: 4.200

2.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Authors:  Jasmine A Luzum; Jason C Cheung
Journal:  Pharmacogenomics       Date:  2018-09-10       Impact factor: 2.533

3.  CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller
Journal:  Pharm Res       Date:  2017-02-08       Impact factor: 4.200

4.  The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.

Authors:  James S Floyd; Bruce M Psaty
Journal:  Diabetes Care       Date:  2016-11       Impact factor: 19.112

5.  Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education.

Authors:  Jasmine A Luzum; Matthew J Luzum
Journal:  Per Med       Date:  2016-03-01       Impact factor: 2.512

Review 6.  Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.

Authors:  Guo Yu; Guo-Fu Li; John S Markowitz
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-09       Impact factor: 2.576

Review 7.  Evidence and resources to implement pharmacogenetic knowledge for precision medicine.

Authors:  Kelly E Caudle; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Mary V Relling; Teri E Klein
Journal:  Am J Health Syst Pharm       Date:  2016-12-01       Impact factor: 2.637

8.  Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program.

Authors:  Daniel L Hertz; Andrew Glatz; Amy L Pasternak; Robert J Lonigro; Pankaj Vats; Yi-Mi Wu; Bailey Anderson; Erica Rabban; Erika Mora; Kevin Frank; Dan R Robinson; Rajen J Mody; Arul Chinnaiyan
Journal:  JCO Precis Oncol       Date:  2018-07-23

Review 9.  The pharmacogenomics of drug resistance to protein kinase inhibitors.

Authors:  Nancy K Gillis; Howard L McLeod
Journal:  Drug Resist Updat       Date:  2016-07-05       Impact factor: 18.500

Review 10.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.